Cargando…

Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder

BACKGROUND: Buprenorphine-naloxone is a medication shown to improve outcomes for individuals seeking treatment for opioid use disorder (OUD); however, outcomes are limited by low medication adherence rates. This is especially true during the early stages of treatment. METHODS: The present study prop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peter, Samuel C., Murphy, James G., Witkiewitz, Katie, Hand, Sarah B., Thomas, Fridtjof, Johnson, Karen Chandler, Cowan, Ronald, Harris, Matt, Derefinko, Karen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061866/ https://www.ncbi.nlm.nih.gov/pubmed/36991453 http://dx.doi.org/10.1186/s13063-023-07102-9

Ejemplares similares

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder
por: Binger, Katie J., et al.
Publicado: (2020)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
por: Blazes, Christopher K., et al.
Publicado: (2020)

Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
por: Mauger, Sofie, et al.
Publicado: (2014)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
por: Soyka, Michael
Publicado: (2015)

Opioid Drug Utilization and Cost Outcomes Associated With the Use of Buprenorphine-Naloxone in Patients With a History of Prescription Opioid Use
por: Kaur, Aman Deep, et al.
Publicado: (2008)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States
por: Sun, Tianyu, et al.
Publicado: (2022)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Successful Management of Kratom Use Disorder With Buprenorphine and Naloxone
por: Arhin, Martin, et al.
Publicado: (2023)

Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder
por: Kapuganti, Amber, et al.
Publicado: (2018)

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
por: Bestepe, Engin Emrem, et al.
Publicado: (2020)

Comment on “A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence During Pregnancy: Maternal and Neonatal Outcomes”
por: Newman, Robert G., et al.
Publicado: (2013)

Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
por: Martin, Yvette N., et al.
Publicado: (2019)

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence
por: Ghosh, Abhishek, et al.
Publicado: (2022)

Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan
por: Goshgarian, Gregory, et al.
Publicado: (2022)

Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
por: Regenstreif, Lori, et al.
Publicado: (2022)

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder
por: Wipper, Benjamin, et al.
Publicado: (2023)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
por: McCormack, Lindsay, et al.
Publicado: (2021)

Disparities in Emergency Department Naloxone and Buprenorphine Initiation
por: Papp, Joan, et al.
Publicado: (2023)

A case report on the treatment of complex chronic pain and opioid dependence by a multidisciplinary transitional pain service using the ACT Matrix and buprenorphine/naloxone
por: Weinrib, Aliza Z, et al.
Publicado: (2017)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder
por: Schellekens, Arnt F. A., et al.
Publicado: (2021)

Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
por: Ellerbroek, Hannah, et al.
Publicado: (2022)

Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
por: Bastien, Gabriel, et al.
Publicado: (2022)

The use of buprenorphine/naloxone to treat borderline personality disorder: a case report
por: Hansen, Brenna, et al.
Publicado: (2022)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study
por: Håkansson, A., et al.
Publicado: (2016)

Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone
por: Kline, Anna, et al.
Publicado: (2023)

Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series
por: Cedeño, Erica, et al.
Publicado: (2022)

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
por: Gu, Meng, et al.
Publicado: (2023)

Thematic Analysis of Reddit Content About Buprenorphine-naloxone Using Manual Annotation and Natural Language Processing Techniques
por: Graves, Rachel Lynn, et al.
Publicado: (2022)

A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
por: Simojoki, Kaarlo, et al.
Publicado: (2008)

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone(®)) in Spain
por: Martinez-Raga, Jose, et al.
Publicado: (2012)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone
por: Gawronski, Kristen M, et al.
Publicado: (2014)

Yoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone
por: Lander, Laura, et al.
Publicado: (2017)

Sexual dysfunction in men on buprenorphine – naloxone-based substitution therapy
por: Mattoo, Surendra K., et al.
Publicado: (2020)

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs
por: Scott, Travis M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6tlt0gh9474iml71bf9ihipps0